Nuvalent, Inc. (NUVL) surged 14.24% to $110.24, up $13.74, following an announcement of strong topline data from its pivotal ALKOVE-1 trial evaluating neladalkib (NVL-655) in TKI-pretreated patients with ALK-positive non-small cell lung cancer (NSCLC).
The results showed meaningful improvements in response rates and durability, positioning neladalkib as a potential best-in-class ALK inhibitor in a heavily pretreated setting.
The trial data excited investors and triggered heavy trading volume in NUVL shares. The stock's 52-week range is $55.30 - $110.24.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.